News of Note—Themis’ Chikungunya vaccine, Gardasil protests and more

non
(Pixabay)

Here is some other vaccine news of note for the week.

> The European Medicines Agency has granted Themis’ phase 2 chikungunya vaccine candidate Priority Medicines (PRIME) designation, which is designed to provide enhanced regulatory support. Release

> A group of women protested at Merck’s office in Hong Kong to express their unhappiness over a shortage of Gardasil 9 in the area and to urge the firm to increase the supply. South China Morning Post article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Healthcare mogul Patrick Soon-Shiong plans to take public a cancer vaccine biotech later this year to finance the development of six candidates currently in clinical trials against nine tumor types. FierceBiotech article

> The FDA granted a priority review for Merck's Gardasil 9 in women and men ages 27 to 45 with a PDUFA date of Oct. 6, 2018. Release